Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response

Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response-1

Edited by
Federico Innocenti

2009

Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response provides the most comprehensive body of knowledge available on the role of genetic and genomic variation in the individualization of drug therapies in cancer patients. As a consequence of the intrinsic chromosomal and genetic instability of the tumor genome, it is generally believed that tailoring of chemotherapy in cancer patients might be achieved by molecular analysis of patient tumor DNA.

Leave a Reply

Your email address will not be published. Required fields are marked *